Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001348048 | SCV001542335 | uncertain significance | Neurofibromatosis, type 2 | 2022-11-25 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Experimental studies are conflicting or provide insufficient evidence to determine the effect of this variant on NF2 function (PMID: 9466988, 9931334, 11535133, 24309211, 24595234). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt NF2 protein function. ClinVar contains an entry for this variant (Variation ID: 1043876). This missense change has been observed in individual(s) with clinical features of neurofibromatosis type 2 (PMID: 7759081). This variant is present in population databases (rs766974263, gnomAD 0.003%). This sequence change replaces lysine, which is basic and polar, with glutamic acid, which is acidic and polar, at codon 413 of the NF2 protein (p.Lys413Glu). |
Baylor Genetics | RCV003462913 | SCV004199040 | uncertain significance | Familial meningioma | 2023-09-19 | criteria provided, single submitter | clinical testing |